--- title: "Cybin Inc. (NASDAQ:HELP) Receives Average Recommendation of \"Buy\" from Analysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/293945921.md" description: "Cybin Inc. (NASDAQ:HELP) has received a consensus 'Buy' rating from five covering analysts, with an average one-year price target of $45.25. TD Cowen and Wells Fargo recently initiated coverage with 'buy' and 'overweight' ratings, respectively. Shares rose 5.0% to $8.00. Institutional investors including Osaic Holdings, Bank of America, and Millennium Management have increased their stakes in the clinical-stage biopharmaceutical company." datetime: "2026-07-27T14:14:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293945921.md) - [en](https://longbridge.com/en/news/293945921.md) - [zh-HK](https://longbridge.com/zh-HK/news/293945921.md) generator: "portal-rs" --- # Cybin Inc. (NASDAQ:HELP) Receives Average Recommendation of "Buy" from Analysts Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have received a consensus rating of "Buy" from the five analysts that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $45.25. - Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise Several research analysts recently commented on the company. TD Cowen began coverage on Cybin in a research report on Monday, April 13th. They set a "buy" rating for the company. Wells Fargo & Company initiated coverage on Cybin in a research note on Monday. They set an "overweight" rating and a $16.00 price objective on the stock. **View Our Latest Analysis on HELP** ## Cybin Stock Up 5.0% Shares of NASDAQ HELP traded up $0.38 during mid-day trading on Monday, hitting $8.00. The company had a trading volume of 190,882 shares, compared to its average volume of 1,075,314. The company has a market cap of $558.96 million, a P/E ratio of -1.89 and a beta of 0.62. The company has a 50-day moving average price of $5.47. Cybin has a one year low of $3.76 and a one year high of $9.12. ## Institutional Trading of Cybin Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its stake in Cybin by 46.7% in the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock valued at $63,000 after acquiring an additional 2,400 shares during the last quarter. Bank of America Corp DE lifted its stake in Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock valued at $247,000 after purchasing an additional 11,790 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock worth $8,414,000 after purchasing an additional 959,448 shares during the period. 17.94% of the stock is owned by institutional investors. ## Cybin Company Profile (Get Free Report) Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need. The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. ## Featured Stories - Five stocks we like better than Cybin - Innovative ETF Strategies That Are Paying Off This Summer - Forget Tesla: These 2 Earnings Reports Reveal Where the Auto Market Is Heading - This Tiny AI Supplier Could Be More Important Than the Chipmakers - Meta Earnings Put AI Spending and Ad Growth Back in Focus *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Cybin Right Now? Before you consider Cybin, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list. While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [HELP.US](https://longbridge.com/en/quote/HELP.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md) - [WFC.US](https://longbridge.com/en/quote/WFC.US.md) - [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md) - [META.US](https://longbridge.com/en/quote/META.US.md) - [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md) - [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md) - [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md) - [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md) - [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md) - [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md) - [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [100,000 Shares in Bank of America Corporation $BAC Purchased by Arini Capital Management Ltd](https://longbridge.com/en/news/297393176.md) - [How To Use A Covered Strangle Trade On This Banking Giant](https://longbridge.com/en/news/297060560.md) - [Argyle Capital Partners LLC Purchases Shares of 9,375 Bank of America Corporation $BAC](https://longbridge.com/en/news/296675010.md) - [Bank of America cuts Hugo Boss voting rights stake to 10.2% from 13.67%](https://longbridge.com/en/news/297056782.md) - [Jupiter Neurosciences says $2 million stock sale lifts equity above Nasdaq minimum listing threshold](https://longbridge.com/en/news/296828047.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**